Neurotrope Bioscience Культура компании

Dr. Susanne Wilke, Ph.D., MBA, has been the President and Chief Executive Officer at CrossBridge International, LLC since August 2011. Dr. Wilke has been the Chief Executive Officer of Neurotrope, Inc. since September 01, 2016 and also served as its President since September 23, 2016. Dr. Wilke has over 15 years operational experience working in leading pharmaceutical and biotechnology companies. She served as Director of Worldwide New Product Assessment for General Medicine and Specialty Pharmaceuticals at Forest Laboratories, as Senior Associate and later Principal at NGN Capital, as Kauffman Fellow in Venture Capital at Schroder Ventures Life Sciences and as Project Leader for Metabolic Diseases at Hoffmann-La-Roche. She joined NGN in 2004. She was Consultant at The Monitor Group in New York From January 2011 to August 2011. She was Principal of NGN BioMed Opportunity I, L.P. She worked at Schroder Ventures Life Sciences, where she served as a Kauffman Fellow focusing on investments in drug products, medical devices and healthcare service companies. Prior to Schroder Ventures, she worked at Amgen Corporation in Strategic Planning responsible for the set-up of the $100 million Amgen Research facility in Boston. Prior to this, Dr. Wilke was in project leadership positions with Hoffmann ??? La Roche and Vertex Pharmaceuticals, where she led research teams in structure based small molecule drug discovery in the metabolic and CNS diseases areas. She serves as a Board Observer at KIKA Medical. She served as an Observer at GlycoFi, Archemix and Phase Forward. She has been a Director of Neurotrope, Inc. since February 15, 2016. She holds a post-doctoral Fellowship with Prof. Dr. Hruby at the University of Arizona. She obtained an M.B.A. from the Tuck School of Business at Dartmouth. Dr. Wilke holds a B.A. in Chemistry from Loyola University, a PhD in Organic Chemistry/Biochemistry and Drug Development from the University of Illinois.

Mr. Robert Weinstein has been the Chief Financial Officer of Neurotrope, Inc. since June 2013 and has been its Executive Vice President since October 1, 2013 and also has been its Secretary and Treasurer since August 23, 2013. Mr. Weinstein has been an Independent Consultant at several healthcare companies in the pharmaceutical and biotechnology industries since September 2011. He serves as Corporate Compliance Officer at Neurotrope, Inc. He joined the Neurotrope in June 2013 as its Acting Chief Financial Officer. He has extensive accounting and finance experience, spanning more than 25 years, as a Public Accountant, Investment Banker, Healthcare Private Equity Fund Principal and as Chief Financial Officer. Mr. Weinstein served as the Chief Financial Officer of Green Energy Management Services Inc. from August 2010 to September 8, 2011. He served as the Chief Financial Officer at Green Energy Management Services Holdings, Inc. from March 2010 to September 8, 2011. He served as the Chief Financial Officer of Xcorporeal, Inc. since August 10, 2007 to February 2010 and served as its Chief Accounting Officer and Secretary. He served as Vice President and Director of Quality Control & Compliance of Citi Private Equity Services. In 2005, he founded and served as Finance & Accounting Consultant of Irvington, NY. He served as Vice President, Treasurer and Principal Accounting Officer of Able Laboratories Inc. from November 2002 to December 29, 2004 and served as its Director of Investor Relations since December 29, 2004. From 2003 to 2004, he served as the Chief Financial Officer of Able Laboratories, Inc. In April 2002, Mr. Weinstein founded EB Associates, LLC and served as the Managing Member until December 2002. At EB Associates, he provided financial consulting for Eurotech, Ltd. Since 2002, he served as Acting Chief Financial Officer of Eurotech, Ltd. From April 2001 to April 2002, he served as the Managing Director of Berliner Communications Inc. From August 1998 to April 2001, he served as the Managing Director and manager of a fund investing in micro-cap private and public companies at Sanders Morris Harris Inc., and from March 1992 to August 1998, he served as the Managing Director and Co-Head of Technology Corporate Finance at Gruntal & Company, L.L.C. He is a Certified Public Accountant in the State of New York. Mr. Weinstein received an MBA in Finance & International Business from the University of Chicago Graduate School of Business and a B.S. in Accounting from the State University of New York at Albany.

Mr. Charles S. Ramat has been consultant at Neurotrope, Inc., since October 03, 2016. Mr. Ramat served as the President of Neurotrope, Inc. from September 12, 2014 to September 23, 2016. Mr. Ramat served as Chief Executive Officer of Neurotrope, Inc. since September 12, 2014 until September 6, 2016. Mr. Ramat served as an Interim Co-Chief Executive Officer at Neurotrope Bioscience, Inc. from July 16, 2014 to September 12, 2014. He has extensive operational and general business experience in several industries including: biotechnology, mdical devices, commercial finance, real estate and mobile communications. From December 2009 to December 2013, he served as consultant to Continental Home Loans, the third largest FHA mortgage originator in New York State. He served as the President and Chief Executive Officer of Kushner Companies LLC from 2002 to 2005. He joined Kushner Companies in 2002 and played a key role in its future growth, focusing on strategic planning. From 1988 to 2002, he served as the Chairman and Chief Executive Officer of Aris Industries, Inc. Prior to 1988, Mr. Ramat acquired various luxury residential buildings in Manhattan where he executed co-op conversions resulting in over $100 million in sales. Also, he was a principal in United Restaurant Corporation. He served as a Principal Investor and Consultant to Continental Home Loans until December 2013. He served as the Chairman and Chief Executive Officer of Aris Industries Inc. Prior to that, he spent a decade as Principal of Ramyork Properties, Inc. He served as Co-Chairman of Neurotrope, Inc. since June 19, 2014 and served as its Director until September 23, 2016. He served as Director of UFood Restaurant Group, Inc., from February 12, 2008 to February 29, 2008. He served on various business company boards, philanthropies and trade organizations. Mr. Ramat graduated cum laude with a B.A. degree from Yeshiva University and earned a Juris Doctor degree from Columbia Law School.

Dr. Daniel L. Alkon, also known as Dan, M.D., has been Scientific Director at Blanchette Rockefeller Neurosciences Institute since 1999. Dr. Alkon has been the Chief Scientific Officer of Neurotrope, Inc. since August 23, 2013. Dr. Alkon serves as Chief Scientific Officer at Neurotrope Bioscience, Inc. Dr. Alkon is a Co-founder of Neurotrope, Inc. and has been its President since September 16, 2016. He began his career in biomedical research. During his 30 year career at NIH, he became a Medical Director in the U.S. Public Health Service at the NINDS and Chief of the Laboratory of Adaptive Systems. As an internationally recognized pioneer in research on brain-based neural networks and the molecular basis of memory, he has authored hundreds of scientific articles as well as several books including Memory Traces in the Brain by Cambridge University Press and the popular book Memory's Voice by Harper Collins. He serves as a Director of Blanchette Rockefeller Neurosciences Institute. He served as a Director of Neurotrope Bioscience, Inc. After earning his M.D. at Cornell University and finishing an Internship in Medicine at the Mt Sinai Hospital in New York, he joined the staff of the National Institutes of Health. He was named as recipient of the Toyota Chair in Neurodegenerative Disease Research for Distinguished Research at the Blanchette Rockefeller Neurosciences Institute in 2006 and is a Professor of Neurology in the West Virginia University School of Medicine. Dr. Alkon received his Undergraduate Degree in Chemistry in 1965 at the University of Pennsylvania, where, with Post-Graduate studies in Physical Chemistry.